ARWR — ARROWHEAD PHARMACEUTICALS INC (Healthcare >> Biotechnology)
ARWR FAQ
What is ARWR's P/E ratio?
ARROWHEAD PHARMACEUTICALS INC (ARWR) currently trades at a P/E ratio of 219.37.
What is ARWR's ROE?
ARROWHEAD PHARMACEUTICALS INC reports a Return on Equity (ROE) of -49.01%.
What is ARWR's dividend yield?
ARROWHEAD PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is ARWR's Deepscope Quality Score?
Deepscope rates ARWR's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARWR?
Deepscope's AI Timing Score for ARWR is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARWR belong to?
ARROWHEAD PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 73.86
Price
-0.53
(-0.72%)
Day Change
|
|
|---|
ARWR Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 73.86 |
| PBV / Sector |
17.19 / 4.75
|
| Earning Per Share | -2.16 |
| PE / Sector |
219.37 / 17.65
|
| PEG or PE/Growth / Sector |
8.73 / 0.52
|
| Average 1M Daily Value |
111.49 M
GREAT
|
| Average 1W Daily Value |
93.31 M
|
| Yếu tố Kỹ thuật |
|
42% |
| Sức khỏe tài chính |
|
43% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-09 09:40:05 |
| Symbol | ARWR |
| Name | ARROWHEAD PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 140.86 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10,295.24 / 9,000.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
Phone: 626 304 3400
Website: https://arrowheadpharma.com
Employees: 711
Sector: Healthcare >> Biotechnology
Description: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google